Alopecia – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Alopecia – Pipeline Review, H2 2017’, provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alopecia

The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects

The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Alopecia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alopecia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Allergan Plc

Almirall SA

AndroScience Corp

Berg LLC

BiologicsMD Inc

BirchBioMed Inc

Brickell Biotech Inc

Bristol-Myers Squibb Company

Cassiopea SpA

Daewoong Pharmaceutical Co Ltd

Dong-A Socio Holdings Co Ltd

Handok Inc

Histogen Inc

Hyundai Pharmaceutical Co Ltd

Incyte Corp

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

LEO Pharma A/S

Medivir AB

NovaLead Pharma Pvt Ltd

Panacea Biotec Ltd

Pfizer Inc

Quark Pharmaceuticals Inc

RXi Pharmaceuticals Corp

Samumed LLC

Switch Biotech LLC

Taisho Pharmaceutical Holdings Co Ltd

Tigo GmbH

viDA Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Alopecia - Overview 7

Alopecia - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Alopecia - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Alopecia - Companies Involved in Therapeutics Development 27

Aclaris Therapeutics Inc 27

Allergan Plc 27

Almirall SA 28

AndroScience Corp 28

Berg LLC 29

BiologicsMD Inc 29

BirchBioMed Inc 30

Brickell Biotech Inc 30

Bristol-Myers Squibb Company 31

Cassiopea SpA 31

Daewoong Pharmaceutical Co Ltd 32

Dong-A Socio Holdings Co Ltd 32

Handok Inc 33

Histogen Inc 33

Hyundai Pharmaceutical Co Ltd 34

Incyte Corp 34

Kuhnil Pharmaceutical Co Ltd 35

Lee's Pharmaceutical Holdings Ltd 35

LEO Pharma A/S 36

Medivir AB 36

NovaLead Pharma Pvt Ltd 37

Panacea Biotec Ltd 37

Pfizer Inc 38

Quark Pharmaceuticals Inc 38

RXi Pharmaceuticals Corp 39

Samumed LLC 39

Switch Biotech LLC 40

Taisho Pharmaceutical Holdings Co Ltd 40

Tigo GmbH 41

viDA Therapeutics Inc 41

Alopecia - Drug Profiles 42

(cyclosporine A + minoxidil + RT-175) - Drug Profile 42

abatacept - Drug Profile 43

AI-001 - Drug Profile 51

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52

Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile 53

ASCJ-9 - Drug Profile 54

ATI-50001 - Drug Profile 56

ATI-50002 - Drug Profile 57

ATI-50003 - Drug Profile 58

BBI-5000 - Drug Profile 59

BMD-1141 - Drug Profile 60

BMD-1341 - Drug Profile 61

BMD-2341 - Drug Profile 62

BQ-A - Drug Profile 63

BRM-421 - Drug Profile 64

calcitriol - Drug Profile 65

CB-0301 - Drug Profile 66

DHL-HisZnNa - Drug Profile 69

finasteride - Drug Profile 70

finasteride - Drug Profile 71

FOL-005 - Drug Profile 72

HGEN-001 - Drug Profile 75

HL-5945 - Drug Profile 77

HTB-005 - Drug Profile 78

interferon beta-1b - Drug Profile 79

KI-1104 - Drug Profile 80

KI-1105 - Drug Profile 81

LEO-124249 - Drug Profile 82

minoxidil - Drug Profile 83

NLP-602 - Drug Profile 84

OLX-104 - Drug Profile 85

PF-06651600 - Drug Profile 86

PF-06700841 - Drug Profile 87

QPAL-1 - Drug Profile 89

QPAL-2 - Drug Profile 90

RBAG-010 - Drug Profile 91

Recombinant Proteins to Agonize EGFR for Alopecia and Arthritis - Drug Profile 92

Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 93

remetinostat - Drug Profile 94

ruxolitinib phosphate - Drug Profile 97

Samcyprone - Drug Profile 112

setipiprant - Drug Profile 114

SM-04554 - Drug Profile 116

Small Molecule for Androgenic Alopecia - Drug Profile 119

Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 120

Synthetic Peptide for Alopecia - Drug Profile 121

TP-0427736 - Drug Profile 122

TS-133 - Drug Profile 123

VTI-1000 Series - Drug Profile 124

ZK-003 - Drug Profile 125

Alopecia - Dormant Projects 126

Alopecia - Discontinued Products 128

Alopecia - Product Development Milestones 129

Featured News & Press Releases 129

Appendix 138

Methodology 138

Coverage 138

Secondary Research 138

Primary Research 138

Expert Panel Validation 138

Contact Us 138

Disclaimer 139

List of Tables

List of Tables

Number of Products under Development for Alopecia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Alopecia – Pipeline by Aclaris Therapeutics Inc, H2 2017

Alopecia – Pipeline by Allergan Plc, H2 2017

Alopecia – Pipeline by Almirall SA, H2 2017

Alopecia – Pipeline by AndroScience Corp, H2 2017

Alopecia – Pipeline by Berg LLC, H2 2017

Alopecia – Pipeline by BiologicsMD Inc, H2 2017

Alopecia – Pipeline by BirchBioMed Inc, H2 2017

Alopecia – Pipeline by Brickell Biotech Inc, H2 2017

Alopecia – Pipeline by Bristol-Myers Squibb Company, H2 2017

Alopecia – Pipeline by Cassiopea SpA, H2 2017

Alopecia – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Alopecia – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Alopecia – Pipeline by Handok Inc, H2 2017

Alopecia – Pipeline by Histogen Inc, H2 2017

Alopecia – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Alopecia – Pipeline by Incyte Corp, H2 2017

Alopecia – Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2017

Alopecia – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Alopecia – Pipeline by LEO Pharma A/S, H2 2017

Alopecia – Pipeline by Medivir AB, H2 2017

Alopecia – Pipeline by NovaLead Pharma Pvt Ltd, H2 2017

Alopecia – Pipeline by Panacea Biotec Ltd, H2 2017

Alopecia – Pipeline by Pfizer Inc, H2 2017

Alopecia – Pipeline by Quark Pharmaceuticals Inc, H2 2017

Alopecia – Pipeline by RXi Pharmaceuticals Corp, H2 2017

Alopecia – Pipeline by Samumed LLC, H2 2017

Alopecia – Pipeline by Switch Biotech LLC, H2 2017

Alopecia – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017

Alopecia – Pipeline by Tigo GmbH, H2 2017

Alopecia – Pipeline by viDA Therapeutics Inc, H2 2017

Alopecia – Dormant Projects, H2 2017

Alopecia – Dormant Projects, H2 2017 (Contd..1), H2 2017

Alopecia – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Alopecia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports